The Trump administration made a deal with pharmaceutical giants Eli Lilly and Novo Nordisk to lower prices for blockbuster anti-obesity and diabetes medications in the GLP-1 drug class, as well as expand coverage access for Medicare beneficiaries. The deal means the revolutionary drugs will be cover......